Trial Profile
Safety, Tolerability, Pharmacokinetics & Antitumour Activity of AZD9291 in Patients With Advanced Non Small Cell Lung Cancer Who Have Progressed on Prior Therapy With an Epidermal Growth Factor ReceptorTyrosine Kinase Inhibator Agent
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 23 Jan 2024
Price :
$35
*
At a glance
- Drugs Osimertinib (Primary)
- Indications Non-small cell lung cancer
- Focus First in man; Registrational; Therapeutic Use
- Acronyms AURA; AURA extension; AURAext
- Sponsors AstraZeneca; AstraZeneca AB
- 17 Jan 2024 Status changed from active, no longer recruiting to completed.
- 08 Feb 2023 Planned End Date changed from 30 Dec 2022 to 29 Dec 2023.
- 10 Dec 2022 This trial has been completed in Italy according to European Clinical Trials Database record.